Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722122 | 0.97 | MCL1 (0.45) | MCL1CYP19A1LTB4RMEN1RAB9A | |
| SCHEMBL25582624 | 0.95 | MCL1 (0.44) | MCL1CYP19A1LTB4RMEN1RAB9A | |
| SCHEMBL25582672 | 0.94 | MCL1 (0.43) | MCL1CYP19A1LTB4RMEN1RAB9A | |
| SCHEMBL25722098 | 0.88 | MAOB (0.53) | MCL1MEN1KMT2AMAPK1TDP1 | |
| SCHEMBL25722116 | 0.88 | MAOB (0.54) | MEN1KMT2AMAPK1TDP1MAOB | |
| SCHEMBL25722089 | 0.87 | MCL1 (0.52) | MCL1CYP19A1LTB4RMEN1KMT2A | |
| SCHEMBL25722136 | 0.86 | MEN1 (0.50) | MEN1KMT2AMAPK1TDP1MAOB | |
| SCHEMBL25722125 | 0.85 | MEN1 (0.53) | MCL1MEN1KMT2AMAPK1TDP1 | |
| SCHEMBL25722080 | 0.85 | MAOB (0.51) | MEN1KMT2AMAPK1TDP1MAOB | |
| SCHEMBL27253080 | 0.83 | CYP1A1 (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690289-B2 | Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same | LEF1, PPOX, LIMK1 | MCL1 2073/4885CYP19A1 147/4885LTB4R 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.